« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1
, Pages
5-10
, January 2008
Targeting TNF-α: A novel therapeutic approach for asthma
-
Summary of TNF-α biology and signaling. The cascade of events involved in TNF-α signaling and receptor function is shown. See text for details. TACE, TNF-α–converting enzyme; NFκB, nuclear factor κB.
Summary of TNF-α biology and signaling. The cascade of events involved in TNF-α signaling and receptor function is shown. See text for details. TACE, TNF-α–converting enzyme; NFκB, nuclear factor κB.
-
Role of TNF-α in the pathogenesis of asthma. TNF-α plays a central role in many of the features of the asthma paradigm by exerting important effects on both inflammatory and structural cells. See text
Role of TNF-α in the pathogenesis of asthma. TNF-α plays a central role in many of the features of the asthma paradigm by exerting important effects on both inflammatory and structural cells. See text for details.
-
Molecular mechanisms activated in ASM induced by TNF-α–activated molecular mechanisms in ASM possibly contributing to AHR in asthma. TNF-α might modulate AHR through a number of possible mechanisms: (Molecular mechanisms activated in ASM induced by TNF-α–activated molecular mechanisms in ASM possibly contributing to AHR in asthma. TNF-α might modulate AHR through a number of possible mechanisms: (1) enhanced receptor-associated calcium signals as a result of an increased expression, function, or both of the receptor G protein (Gaq or Gai); (2) altered signal transduction, such as increased phospholipase C (PLCβ) expression, activity, or both; (3) abnormal calcium handling by exerting effects on key enzymes that regulate inositol-1,4,5-trisphosphate (IP3) metabolism, such as 5-phosphatase I and II, effects on function, and/or the expression of Ryanodine receptors (RyR), IP3 receptor (IP3R), or calcium ATPases called sarcoendoplasmic calcium ATPases (SERCA), which regulate calcium fluxes, or calmodulin (CaM); and (4) changes in calcium sensitivity mediated by effects on RhoA expression or increases in both myosin light chain kinase (MLCK) or myosin light chain phosphatase (Pase) content, activity, or both. See text for details.
(Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation)
Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD
Supported by Asthma UK, a DOH Clinician Scientist award, and NIH06364.
Disclosure of potential conflict of interest: C. Brightling has consulting arrangements with Cambridge Antibody Technology, GlaxoSmithKline, AstraZeneca, Pfizer, Roche, and Piramed; owns stock in Leicester AIR; has received grant support from AstraZeneca, Cambridge Antibody Technology, and GlaxoSmithKline; and is on the speakers' bureau for AstraZeneca and GlaxoSmithKline. Y. Amrani has received grant support from Centocor and the National Institutes of Health. M. Berry has declared that he has no conflict of interest.
PII: S0091-6749(07)01999-9
doi: 10.1016/j.jaci.2007.10.028
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1
, Pages
5-10
, January 2008
